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.Summary
Neutrophil-derived oxidative stress plays a crucial role in acute lung injury. Hypochlorite/
hypochlorous acid (HOCl) is a major oxidant of neutrophils. Protein kinase C (PKC) may be
an appropriate target for HOCl due to its functionally important thiols. This study
investigates the role of PKC in HOCl-induced acute lung injury.
Isolated lung preparations were from 30 rabbits. HOCl (1000 nmolmin1) or buffer
(control) were infused into isolated rabbit lungs. Pulmonary artery pressure (PAP [Torr])
and lung weight were continuously measured. Capillary filtration coefficient (Kf,c), was
measured at baseline and at 30, 60, 90min. Experiments were terminated at 105min or
when fluid retention exceeded 50 g. The non-selective protein kinase inhibitor
staurosporin (100 nM) or the selective PKC inhibitor bisindolylmaleimide I (GF109203X,
10 nM) were added to the perfusate 5min prior to the start of the experiments.
Staurosporin completely prevented the HOCl-induced increase in PAP (no change versus
DPAPmax 5.270.78) but did not influence the increase in vascular permeability. GF109203X
delayed the HOCl-induced increase in PAP and vascular permeability. PAPmax was observed
significantly later in the HOCl-GF109203X group (84.474.0min) in comparison with the
HOCl group (52.173.5min). Termination of the experiments due to edema formation
occurred significantly later in experiments with GF109203X (91.871.9 versus
79.274.1min).
Protein kinases are involved in HOCl-induced acute lung injury. Specifically PKC inhibition
delayed HOCl-induced increases in PAP and vascular permeability.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
all authors.
9712811;
idt@t-online.deIntroduction
Neutrophils play a crucial role in the pathogenesis of
acute lung injury.1 The sequestration of neutrophils in
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stimuli is regarded as an initiating event of acute res-
piratory distress syndrome.2 It is accompanied by a large
increase in neutrophils and myeloperoxidase activity in
bronchoalveolar lavage fluid.2 Stimulated neutrophils
may affect lung tissue through the release of proteolytic
enzymes,1 the production of prostanoids3 or the gene-
ration of highly reactive oxygen species.1 Oxidative stress
is considered as a major pathway in acute lung injury.
Various experimental models and clinical studies demon-
strate the involvement of oxidative stress in acute lung
injury.4,5
Hypochlorous acid/hypochlorite (HOCl) is the predomi-
nant oxidant of the stimulated neutrophil. HOCl is synthe-
sized by neutrophil-derived myeloperoxidase. This enzyme
targets free functional groups of proteins and amino acids,
predominantly sulfhydryl groups.6 The effects of HOCl on
isolated rabbit lungs are comparable to the effects of
stimulated neutrophils.7 The increase in pulmonary artery
pressure (PAP) and vascular permeability is accompanied by
accumulation of lipid peroxidation products.8 The mechan-
isms mediating HOCl-induced effects during acute lung
injury are not entirely elucidated. However, the following
considerations suggest an involvement of protein kinase C
(PKC).
All PKC isoforms consist of a N-terminal regulatory domain
and a C-terminal catalytic domain. These domains are
connected by flexible hinge regions.9,10 In the resting state,
the enzyme is kept inactive by intramolecular interaction of
an auto-inhibitory sequence (pseudosubstrate) of the
regulatory domain and the substrate-binding site of the
catalytic domain.10 Activation of the enzyme requires the
binding of diacylglycerol (DAG) to the regulatory domain
thus enhancing the affinity of PKC to the cell membrane.9
The binding of phospholipids, such as phosphatidylserine,
and DAG causes conformational changes rendering the
enzyme active.9,10 The DAG binding sites exhibit two pairs
of zinc fingers located at the regulatory site. Each zinc finger
consists of six cysteine residues that coordinate two zinc
atoms.11 This positively charged zinc thiolate structure is
highly susceptible to negatively charged oxidants, such as
the HOCl ion (OCl).12 Oxidative modification of these
cysteine residues destroys the zinc fingers. The auto-
inhibition is relieved and co-factor independent activity is
commenced.13 In addition oxidative stress-induced activa-
tion of phospholipase A2 (PLA2),14 phospholipase C (PLC)15
and phospholipase D (PLD)16 results in the release of DAG
and phospholipids from the cell membrane and subsequently
in co-factor dependent PKC activation. Hydrogen peroxide
has been shown to activate PKC in bovine tracheal smooth
muscle cells.17 PKC activation has been shown to induce
pulmonary vasoconstriction,18 to be involved in pulmonary
hypoxic vasoconstriction19 and to increase endothelial cell
permeability.20
We hypothesized that the acute increase in PAP
and vascular permeability in response to HOCl is mediated
by PKC activation. This study therefore investigates
the influence of PKC inhibition with a non-specific serine-/
threonin kinases inhibitor, Staurosporin, and a
specific inhibitor of PKC (bisindolylmaleimide I; GF
109203X [BIM]) on HOCl-induced increase in PAP and vascular
permeability.Methods
Isolated rabbit lung model
General procedure
Rabbits of either sex between 2.5 and 3.0 kg were used.
Isolated lungs were prepared according to the method
described in detail by Seeger et al.21 and as published
previously.7,22 Lungs were ventilated with a mixture of 4%
CO2, 17% O2 and 79% N2 to maintain perfusate pH between
7.37 and 7.40. A rodent animal respirator was used. The
ventilatory frequency was set to 30min1. Positive end-
expiratory pressure was set to 2 cmH2O and tidal volume was
set to 30ml. Perfusion flow was gradually increased to
100mlmin1. Krebs–Henseleit buffer (NaCl 125mM, KCl
4.3mM, glucose 13.32mM, KH2PO4 1.1mM, MgCl2 1.3mM,
CaCl2 2.4mM, NaHCO3 24mM) was used for perfusion. The
total volume of the re-circulating perfusate was 300ml and
perfusate temperature was kept at 37 1C. PAP, pulmonary
venous pressure, ventilation pressure and weight gain of the
isolated organ were continuously recorded. Following a
steady-state period only those lungs were selected for the
study that fulfilled entry conditions: no signs of leakage, a
homogeneous white appearance, lack of macroscopically
visible edema, no increase in lung weight. Pulmonary venous
pressure was adjusted to 2mmHg.
Hydrostatic challenge
Capillary filtration coefficient (Kf,c) was determined grav-
imetrically from the slope of lung weight gain after a sudden
venous pressure elevation of 10 cmH2O for 8min.
21 It was
expressed as 104ml s1 cmH2O
1 g1. The total rapid
change in weight over the first 2min following the onset of
the venous pressure rise was designated as pure vascular
filling and used for the calculation of vascular compliance
(C, [g cmH2O
1]).21 Retention (DW, [g]) was determined as
the remaining difference in weight before and after a
hydrostatic challenge.
Substances
BIM was purchased from Calbiochem (Darmstadt, Germany).
All other reagents were obtained from Sigma (Munich,
Germany). The concentration of the HOCl stock solution
was determined spectrophotometrically (e290 nm ¼ 350mol1
cm1) immediately before use.
Perfusate concentrations of potassium and lactate
dehydrogenase activity
Potassium concentration and lactate dehydrogenase were
used to exclude severe tissue damage. The measurements
were performed by standard methods.
Experimental protocol
Experimental groups are summarized in Table 1. The
continuous application of 1000 nmolmin1 HOCl (HOCl
group) or of buffer for control (C group) into the arterial
line of the system was started at t ¼ 0min following a
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Table 1 Experimental groups.
Group n HOCl (continuous
infusion)
Addition of (at
t ¼ 5min)
Time of termination of the
experiment (t)
C 4 None 105min
C-Stau 4 None Staurosporin 100 nM 105min
C-BIM 4 None BIM 10 nM 105min
HOCl 6 1000 nmolmin1 105min or time when fluid
retention exceed 50 gHOCl-Stau 6 1000 nmolmin1 Staurosporin 100 nM
HOCl-BIM 6 1000 nmolmin1 BIM 10 nM
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Figure 1 Time course of pulmonary artery pressure increase:
Change in PAP (DPAP) over time in controls (upper panel, A) and
HOCl treated lungs (lower panel, B). Control lungs without
inhibitor are characterized by a square. Staurosporin (100 nM)
or BIM (10 nM) treated lungs are characterized by circle
(staurosporin) or triangle (BIM). *po0.05 versus corresponding
control; ypo0.05 versus HOCl group.
PKC in hypochlorite-induced acute lung injury 120730min steady-state period and a baseline hydrostatic
challenge at t ¼ 15min. HOCl was diluted in the perfu-
sate. The flow rate of HOCl or buffer infusion was
0.5mlmin1.
Hydrostatic challenges were performed at 30, 60 and
90min. PAP was continuously recorded.
The PKC inhibitor staurosporin (100 nM, Stau groups) or
BIM (10 nM BIM groups) were added into the perfusate 5min
prior to the start of HOCl or buffer (for control) application.
HOCl administration increases vascular permeability. This
results in fluid retention and pulmonary edema. Continuing
of the perfusion experiment with severe edematous lungs
does not result in meaningful registrations. Therefore, a
cut-off was defined to terminate the experiments. An
increase in weight of 50 g or more represented severe
edema and was therefore defined as a cut-off for premature
termination of the experiments. Experiments were termi-
nated at 105min or when the increase in lung weight due to
fluid retention exceeded the cut-off of 50 g. The time period
from the start of oxidant infusion to the termination of the
experiment was regarded as experimental time.
We did not find measurable concentrations of HOCl in the
venous line of our isolated lung preparation under infusion
of the oxidant. Therefore the oxidant was obviously
consumed during the first passage through the lung and no
accumulation of oxidants in the perfusate was likely to
occur. Potassium concentration and lactate dehydrogenase
activity were measured immediately prior to hydrostatic
challenges.
Statistical methods
Data are indicated as means7SEM. Analysis for statistical
significance was performed by two tailed Student’s t-test for
unpaired samples including Bonferoni correction for multi-
ple testing.
Results
Pulmonary artery pressure response
Figure 1 depicts the time course of the change in PAP of all
experimental groups. There was no pressure response in the
control groups indicating that PKC inhibitors used in this
study did not affect PAP of in the absence of HOCl. HOCl
expectedly led to a considerable increase in PAP. The HOCl-
induced pressure response was completely inhibited by
staurosporin (100 nM). No significant increase in PAP wasobserved in the HOCl-Stau group. BIM (10 nM) in contrast led
to a delay of the pressure response. Maximum PAP was
observed significantly later in the HOCl-BIM group (at
84.474.0min) in comparison with the HOCl group
(52.173.5min). In addition, the increase in PAP was
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group in comparison with the HOCl group.
Premature termination of the experiments due to severe
edema formation occurred in all groups following HOCl
administration (Fig. 2). Figure 1 therefore lists only those
time points that were reached in all experiments of the
experimental groups.
Figure 3 summarizes baseline and maximum PAP of all
experimental groups. No differences existed in baseline PAP
among the experimental groups. A significant difference
between baseline and maximum PAP was observed in the
HOCl group and the HOCl-BIM group but was not observed in
the HOCl-Stau group. Thus Staurosporin completely pre-
vented the HOCl-induced pressure response, whereas addi-
tion of BIM resulted in a delay of the pressure response.control
control Stau
control BIM
HOCl
HOCl Stau
HOCl BIM
0 30 60 90
†
*
*
*
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Figure 2 Mean experimental time: Experiments were termi-
nated at 105min or when the increase in lung weight due to
fluid retention exceeded 50 g. This time is depicted as the mean
experimental time for each group. *po0.05 versus correspond-
ing control; ypo0.05 versus HOCl group.
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Figure 3 Baseline and maximum pulmonary artery pressure: Base
groups. *po0.05 versus corresponding baseline PAP.Oxidant-induced effects on vascular permeability
The changes in vascular permeability are summarized in
Fig. 4. There were no changes in capillary filtration
coefficient and fluid retention in the control groups. HOCl
induced a significant increase of approximately 10 fold in
fluid retention and a significant increase of approximately 6
fold in capillary filtration coefficient at 60min. While
Staurosporin did not exhibit any influence on HOCl-induced
increase in vascular permeability, BIM completely inhibited
this increase in vascular permeability at 60min. These
differences in vascular permeability also resulted in differ-
ences of the length of the experiments. Severe edema
formation resulted in premature termination of experiments
in the HOCl groups (as indicated above in Fig. 2). Mean
duration of experiments was significantly longer in HOCl
experiments with added BIM. Vascular compliance (Table 2)
remained unchanged during HOCl administration indicating
that the increase of lung weight was due to changes in
microvascular permeability rather than increased vascular
filling. The addition of oxidant did not lead to changes in
vascular compliance.
Because PAP did not exceed 18mmHg, the formation of
hydrostatic edema was not expected.Discussion
HOCl, a predominant oxidant in acute lung injury, induces an
increase in pulmonary vascular permeability and PAP. In this
study, we describe influences of the non-selective protein
kinase inhibitor Staurosporin and the PKC-inhibitor BIM on
these effects of HOCl in a ventilated and perfused lung
model. Staurosporin completely inhibited HOCl-induced PAP
increase but did not influence HOCl-induced increase in
vascular permeability. BIM significantly delayed the HOCl-
induced increase in PAP and vascular permeability.
Staurosporin is a non-selective protein kinase inhibitor,
which also inhibits protein kinase A (IC50 ¼ 7.0 nM23) or*
*
HOCl HOCl Stau HOCl BIM
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Figure 4 Vascular permeability: Fluid retention (DW, panels A and C) and capillary filtration coefficient (Kf,c expressed as
104ml s1 cmH2O
1 g1, panels B and D) registered during hydrostatic challenges. Upper panels show controls (A and B), lower
panels show HOCl experiments (C and D). Experiments without PKC inhibitor are characterized by a square. Experiments with
staurosporin (100 nM) or BIM (10 nM) are characterized by circles (staurosporin) and triangles (BIM). *po0.05 versus corresponding
control; ypo0.05 versus HOCl group.
Table 2 Vascular compliance measured during hydrostatic challenges.
Group Hydrostatic challenge
Base line t ¼ 15min t ¼ 30min t ¼ 60min t ¼ 90min
C [g cmH2O
1]
C 0.3670.032 0.3470.020 0.3470.026 0.3470.035
C-Stau 0.3970.036 0.3870.036 0.4070.041 0.4070.040
C-BIM 0.3670.041 0.3570.032 0.3670.025 0.3770.046
HOCl 0.3170.028 0.3370.014 0.3070.010 
HOCl-Stau 0.3570.039 0.3570.039 0.3170.041 
HOCl-BIM 0.2870.019 0.2870.019 0.2770.019 
Premature termination of the experiments due to severe edema formation indicated by an increase in lung weight gain of more
than 50 g.
PKC in hypochlorite-induced acute lung injury 1209myosin light chain kinase (MLCK; IC50 ¼ 1.3 nM24). Stauros-
porin has been reported to inhibit PKC at very low
concentrations (IC50 ¼ 0.7 nM23). The staurosporin concen-
tration in this study was chosen to inhibit all of these protein
kinases. Inhibition of MLCK by a selective MLCK inhibitor as
well as by staurosporin has been demonstrated to inhibit
oxidative stress-induced vasoconstriction.25 Inhibition of
HOCl-induced PAP increase by staurosporin may therefore
be partially due to MLCK inhibition.
BIM is regarded as a highly selective PKC inhibitor with an
inhibitory effectiveness comparable to that of staurosporinfor PKC (IC50: 10 nM26). The IC50 dose was used in this study
to reduce possible non-specific effects at higher concentra-
tions.
The distinct effects of staurosporin and BIM are in
accordance with observations in other experimental models
and may well be explained by the differences in selectiv-
ity.27 The distinct effects of staurosporin and BIM on the
HOCl-induced increase in PAP and vascular permeability
therefore indicate that PKC but also other protein kinases
are involved in HOCl-induced changes in PAP and vascular
permeability.
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effects of oxidative stress on PAP and vascular permeability.
A number of PKC isoenzymes are involved in a variety of
diverse cellular functions,28 including the regulation of cell
permeability and cell contraction.18 Changes in pulmonary
endothelial cell permeability as well as contraction of these
cells may increase vascular permeability, whereas contrac-
tion of pulmonary vascular smooth muscle cells may
contribute to pulmonary vascular pressure response. Acti-
vated PKC may thus be involved in the increase in PAP as
well as in the increase in pulmonary vascular permeability as
has been observed in this study.
These results are in accordance with previous studies
indicating an involvement of PKC activation in the increase
in PAP18 and increase in endothelial permeability20 following
oxidant challenge.
There is further evidence for a role of PKC in oxidative
stress-induced increase in PAP and vascular permeability:
hydrogen peroxide-induced increase in PAP and capillary
filtration coefficient was found to be reduced by PKC
inhibition in a model of isolated guinea pig lungs.29 The
hydrogen peroxide-induced increase in permeability of the
endothelial monolayer has also been shown to be reduced by
PKC inhibition.30 Hydrogen peroxide, as HOCl, is a non-
radical oxidant. Although there are differences in the time
course of the HOCl and hydrogen peroxide-induced changes
in PAP and vascular permeability, equivalent concentrations
of both oxidants have been shown to increase PAP and
vascular permeability in isolated rabbit lungs.31 PKC activa-
tion seems to be involved in hydrogen peroxide as well as in
HOCl-induced acute changes in PAP and vascular perme-
ability.
Oxidative stress may activate PKC by several distinct
mechanisms: (i) Direct oxidative modification of thiol
residues of the N-terminal regulatory domain relieving the
auto-inhibition and permitting co-factor independent acti-
vation.13 (ii) Oxidative stress has been shown to induce
PLA2-, PLC- and PLD-mediated generation of activators and
cofactors by oxidative activation of these phospholi-
pases.14,15 PLA2 also releases arachidonic acid with subse-
quent activation of pulmonary prostanoid metabolism.
Pulmonary prostanoids are also involved in HOCl-induced
acute lung injury.32,33 The stimulation of pulmonary prosta-
noid metabolism may explain why PKC inhibition with BIM
only partially reduced HOCl-induced effects.
HOCl is a highly reactive neutrophil-derived compound. It
oxidizes free functional groups of proteins with great
reactivity. This study uses an isolated lung preparation with
protein-free buffer perfusion. The use of protein-free buffer
prevents inactivation of the oxidant infused into the
perfusate.6,34 The use of an isolated lung preparation allows
to study the effects of PKC inhibition in the lung without
possibly interfering influences of other organ systems and
the systemic circulation. This model does not allow direct
conclusions regarding the effects of PKC inhibitors in clinical
situations.
The use of PKC inhibitors has modified the effects of HOCl
in our isolated lung model. However, this provides only
indirect evidence for an involvement of PKC in this model of
HOCl-induced lung injury. The inhibitors used here did not
induce any measurable effects in control experiments. It
may, therefore, be concluded, that the effects observed inthis study in lungs treated with HOCl oxidant are subsequent
to protein kinase inhibition.
The dosages of PKC inhibitors used in this study have been
deduced from data in the literature obtained in different
models and different species. Although, the use of a single
dose of both inhibitors may represent a limitation in the
interpretation of the specific effect of these inhibitors it
appears sufficient to prove the involvement of PKC in
oxidative stress-induced lung injury.
PKC belongs to a large family of serine/threonine protein
kinases with more than 10 isoforms, which are classified
according to their cofactor requirement. Calcium-indepen-
dent PKC delta and PKC zeta as well as calcium-dependent
PKC alpha have all been demonstrated in lung tissue.35 This
study does not allow identifying the isoform that mediates
oxidative stress-induced increase in PAP and vascular
permeability. However, data from the literature suggests,
that it is classic, calcium-dependent PKC that mediates the
observed changes in endothelial permeability and vascular
tone.20References
1. Gadek JE. Adverse effects of neutrophils on the lung. Am J Med
1992;92:27S–31S.
2. Weiland JE, Davis WB, Holter JF, Mohammed JR, Dorinsky PM,
Gadek JE. Lung neutrophils in the adult respiratory distress
syndrome: clinical and pathophysiologic significance. Am Rev
Respir Dis 1986;133:218–25.
3. Feinmark SJ, Cannon PJ. Endothelial cell leukotriene C4
synthesis results from intercellular transfer of leukotriene A4
synthesized by polymorphonuclear leukocytes. J Biol Chem
1986;261:16466–72.
4. Soncul H, Oz E, Kalaycioglu S. Role of ischemic preconditioning
on ischemia-reperfusion injury of the lung. Chest
1999;115:1672–7.
5. Davreux CJ, Soric I, Nathens AB, et al. N-acetyl cysteine
attenuates acute lung injury in the rat. Shock 1997;8:432–8.
6. Arnhold J, Hammerschmidt S, Arnold K. Role of functional
groups of human plasma and luminol in scavenging of NaOCl and
neutrophil-derived hypochlorous acid. Biochim Biophys Acta
1991;1097:145–51.
7. Hammerschmidt S, Wahn H. Comparable effects of HOCl and of
FMLP-stimulated PMN on the circulation in an isolated lung
model. Am J Respir Crit Care Med 1997;156:924–31.
8. Hammerschmidt S, Buchler N, Wahn H. Tissue lipid peroxidation
and reduced glutathione depletion in hypochlorite-induced lung
injury. Chest 2002;121:573–81.
9. Bell RM, Burns DJ. Lipid activation of protein kinase C. J Biol
Chem 1991;266:4661–4.
10. Nishizuka Y. Intracellular signaling by hydrolysis of phospholi-
pids and activation of protein kinase C. Science
1992;258:607–14.
11. Quest AF, Bloomenthal J, Bardes ES, Bell RM. The regulatory
domain of protein kinase C coordinates four atoms of zinc. J
Biol Chem 1992;267:10193–7.
12. Crow JP, Beckman JS, McCord JM. Sensitivity of the essential
zinc-thiolate moiety of yeast alcohol dehydrogenase to hypo-
chlorite and peroxynitrite. Biochemistry 1995;34:3544–52.
13. Gopalakrishna R, Jaken S. Protein kinase C signaling and
oxidative stress. Free Radic Biol Med 2000;28:1349–61.
14. Chakraborti S, Gurtner GH, Michael JR. Oxidant-mediated
activation of phospholipase A2 in pulmonary endothelium. Am
J Physiol 1989;257:L430–7.
ARTICLE IN PRESS
PKC in hypochlorite-induced acute lung injury 121115. Wang XT, McCullough KD, Wang XJ, Carpenter G, Holbrook NJ.
Oxidative stress-induced phospholipase C-gamma 1 activation
enhances cell survival. J Biol Chem 2001;276:28364–71.
16. Natarajan V, Taher MM, Roehm B, et al. Activation of
endothelial cell phospholipase D by hydrogen peroxide and
fatty acid hydroperoxide. J Biol Chem 1993;268:930–7.
17. Abe MK, Kartha S, Karpova AY, et al. Hydrogen peroxide
activates extracellular signal-regulated kinase via protein
kinase C, Raf-1, and MEK1. Am J Respir Cell Mol Biol
1998;18:562–9.
18. Barman SA. Potassium channels modulate canine pulmonary
vasoreactivity to protein kinase C activation. Am J Physiol
1999;277:L558–65.
19. Weissmann N, Voswinckel R, Hardebusch T, et al. Evidence for a
role of protein kinase C in hypoxic pulmonary vasoconstriction.
Am J Physiol 1999;276:L90–5.
20. Lum H, Roebuck KA. Oxidant stress and endothelial cell
dysfunction. Am J Physiol Cell Physiol 2001;280:C719–41.
21. Seeger W, Walmrath D, Menger M, Neuhof H. Increased lung
vascular permeability after arachidonic acid and hydrostatic
challenge. J Appl Physiol 1986;61:1781–9.
22. Hammerschmidt S, Sandvoss T, Gessner C, Schauer J, Wirtz H.
High in comparison with low tidal volume ventilation aggravates
oxidative stress-induced lung injury. Biochim Biophys Acta
2003;1637:75–82.
23. Burnatowska-Hledin M, Zhao P, Capps B, et al. VACM-1, a cullin
gene family member, regulates cellular signaling. Am J Physiol
Cell Physiol 2000;279:C266–73.
24. Tamaoki T, Nomoto H, Takahashi I, Kato Y, Morimoto M, Tomita F.
Staurosporine, a potent inhibitor of phospholipid/Ca++ depen-
dent protein kinase. Biochem Biophys Res Commun
1986;135:397–402.
25. Tzeng HP, Yang RS, Ueng TH, Lin-Shiau SY, Liu SH. Motorcycle
exhaust particulates enhance vasoconstriction in organ cultureof rat aortas and involve reactive oxygen species. Toxicol Sci
2003;75:66–73 [Epub 2003 Jun 2012].
26. Toullec D, Pianetti P, Coste H, et al. The bisindolylmaleimide GF
109203X is a potent and selective inhibitor of protein kinase C. J
Biol Chem 1991;266:15771–81.
27. Lee SK, Stern PH. Divergent effects of protein kinase C
(PKC) inhibitors staurosporine and bisindolylmaleimide I
(GF109203X) on bone resorption. Biochem Pharmacol 2000;60:
923–6.
28. Dempsey EC, Newton AC, Mochly-Rosen D, et al. Protein kinase
C isozymes and the regulation of diverse cell responses. Am J
Physiol Lung Cell Mol Physiol 2000;279:L429–38.
29. Johnson A, Phillips P, Hocking D, Tsan MF, Ferro T. Protein kinase
inhibitor prevents pulmonary edema in response to H2O2. Am J
Physiol 1989;256:H1012–22.
30. Siflinger-Birnboim A, Goligorsky MS, Del Vecchio PJ, Malik AB.
Activation of protein kinase C pathway contributes to hydrogen
peroxide-induced increase in endothelial permeability. Lab
Invest 1992;67:24–30.
31. Hammerschmidt S, Wahn H. The oxidants hypochlorite and
hydrogen peroxide induce distinct patterns of acute lung injury.
Biochim Biophys Acta 2004;1690:258–64.
32. Wahn H, Hammerschmidt S. Influence of cyclooxygenase and
lipoxygenase inhibitors on oxidative stress-induced lung injury.
Crit Care Med 2001;29:802–7.
33. Wahn H, Ruenauver N, Hammerschmidt S. Effect of arachidonic
and eicosapentaenoic acids on acute lung injury induced by
hypochlorous acid. Thorax 2002;57:1060–6.
34. Fliss H. Oxidation of proteins in rat heart and lungs by
polymorphonuclear leukocyte oxidants. Mol Cell Biochem
1988;84:177–88.
35. Wetsel WC, Khan WA, Merchenthaler I, et al. Tissue and cellular
distribution of the extended family of protein kinase C
isoenzymes. J Cell Biol 1992;117:121–33.
